HLS
is a Canada-based biopharmaceutical company that acquires and commercializes novel therapeutics for the treatment of central nervous system and cardiovascular diseases... Read moreHLS
is a Canada-based biopharmaceutical company that acquires and commercializes novel therapeutics for the treatment of central nervous system and cardiovascular diseases... Read more
News
Mar 13, 2025
Marketscreener
HLS: HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid
Mar 13, 2025
Marketscreener
HLS: HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024
Nov 07, 2024
Yahoo
HLS: HLS Therapeutics Announces Q3 2024 Financial Results
Aug 28, 2024
Yahoo
HLS: HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference
Aug 10, 2024
Yahoo
HLS: HLS Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
Jul 29, 2024
Cision Canada
Press Release: HLS : HLS Announces Reimbursement for Vascepa under Alberta's Provincial Drug Plan
Jul 12, 2024
Global Legal Chronicle
HLS: DRI Healthcare Trust's Acquisition Of XENPOZYME From HLS Therapeutics Inc.
Jul 08, 2024
PE Hub Network
HLS: DRI Healthcare Trust buys second royalty interest in Xenpozyme's net sales
May 27, 2024
Owler
HLS Therapeutics, Inc.: HLS's revenue changed from $61.47M in Dec 2022 to $59.38M in Mar 2024
May 09, 2024
Yahoo
HLS: HLS Therapeutics Announces Q1 2024 Financial Results
HLS Competitors
1
2
3
4
5
6
7
8
9
10